Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy.A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.GLP-1s are practically everywhere – roughly one in eight U.S. adults take one. But stopping those drugs may come at a cost. That's according to a new study from the Washington University School of Medicine, which was published on Wednesday in BMJ Medicin ...

Cryptocurrency exchange Kraken has paused its initial public offering (IPO) plans until market conditions improve, CoinDesk reported Wednesday (March 18), citing unnamed sources.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logi ...

UNH, Eli Lilly, and Other Healthcare Stocks Are Trading at a Deep Discount - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.Healthcare Stocks Are Trading at a Deep Discount. Eli Lilly and Others Are Worth a Look.By Jacob SonenshineShareResizeR ...

As you can see on the chart, in April 2025 when Eli Lilly reached the $890 level, it hit resistance. A reversal and move lower followed. When this happened, many of the traders and investors who sold were glad they did.But in October, the stock rallied. The resistance broke. Many investors who were happy when they sold changed their minds. They decided that selling was a mistake.Many of these disgruntled sellers vowed to buy their shares back if they could eventually get them at the same price they were sol ...

Key Takeaways LLY shares fell 5.9% after an HSBC downgrade citing U.S. pricing pressure and rising obesity-drug competition.HSBC warned that pricing pressure and affordability push could reshape competition in the obesity drug market.Continued availability of compounded tirzepatide in the U.S. could divert demand from LLY's branded drugs.Eli Lilly (LLY) remains a dominant player in the global obesity market, with much of its recent growth driven by itsblockbuster tirzepatide (GLP-1) injections, Mounjaro for ...

Eli Lilly and Company (NYSE:LLY) is one of the best ethical companies to invest in now according to Reddit. Eli Lilly and Company (NYSE:LLY) was downgraded to Reduce from Hold by HSBC on March 17, with the firm bringing the price target on the stock down to $850 from $1,070. The firm told investors in a research note that it believes expectations for the total addressable market for obesity are elevated at over $150 billion, and the market is likely to be in the range of $80 billion -$120 billion by 2032, ...

Group 1 - Zhipu AI (02513) saw a price increase of over 10% during trading, currently up 7.4%, following the announcement of its first closed-source model GLM-5-Turbo and a 20% price hike for its new model API [1] - Capital Airport (00694) dropped over 4% after JPMorgan downgraded its investment rating from "Neutral" to "Underweight" and cut the target price by 40% to HKD 1.8, citing structural challenges and potential selling pressure from being removed from the Hong Kong Stock Connect list [1] - Cloudwalk Technology (02670) rose over 7% after signing a strategic cooperation agreement with SF Express to define new standards for building delivery [1] Group 2 - Yiming Anke-B (01541) increased by over 8% after receiving approval for its II phase clinical study of IMM0306 for treating Primary Membranous Nephropathy [2] - WanGuo Data-SW (09698) surged over 12.6% after reporting a net revenue of RMB 11.4323 billion (USD 1.6348 billion) for the year, a 10.8% year-on-year increase, with adjusted EBITDA also up by 10.8% [2] - Automotive stocks collectively fell, with Li Auto-W (02015) down 6.24%, Xpeng Motors-W (09868) down 4.35%, and Great Wall Motors (02333) down 2.64%, amid warnings from multiple CEOs about rising chip costs [2] Group 3 - Smoore International (06969) opened slightly higher but fell 15.21% after reporting a revenue of approximately RMB 14.256 billion for 2025, a 20.8% increase, but a net profit decline of 18.5% [3] - China Cosco Shipping Energy Transportation (01138) rose 5.39% as reports indicated significant impacts on the tanker and energy markets due to ongoing Middle East conflicts [3] Group 4 - China Oriental Education (00667) increased by 6.57% after reporting a revenue of RMB 4.616 billion for 2025, a 12.1% year-on-year increase, with net profit up 47.5% [4] - Changfeng Pharmaceutical (02652) surged over 21%, currently up 9.99%, after announcing the acceptance of its IND application for a new inhalation powder for treating pulmonary arterial hypertension [4] Group 5 - Swarmer (SWMR.US) debuted on the US stock market with a staggering opening price increase of 315.4%, currently up 520%, focusing on AI-driven drone swarm control systems [5] - 36Kr (KRKR.US) rose 37.39% after reporting a total revenue of RMB 227 million for 2025, with a gross margin increase to 58% and a net profit of approximately RMB 11.42 million [5] - Space-related stocks saw active trading, with Rocket Lab (RKLB.US) up 10.21% and Planet Labs PBC (PL.US) up 10.08% [5] Group 6 - Solaris Energy Infrastructure (SEI.US) rose 10.88% after announcing agreements worth USD 620 million to add approximately 900 MW of gas turbine capacity between 2026 and 2029 [7] - Uber (UBER.US) increased by 4.19% following a partnership with NVIDIA to deploy autonomous taxi fleets in major US cities by 2027 [8] - Aiko Solar (CSIQ.US) rose 1.94% after announcing a supply agreement for a 500 MW energy storage project [8] - Atour (ATAT.US) saw a price increase of 5.98% after reporting a net revenue of approximately RMB 2.788 billion for Q4 2025, a 33.8% year-on-year increase [8]

Airline and Travel Companies - Shares of airlines and travel companies rebounded, with Delta rising more than 6%, Norwegian Cruise Line Holdings climbing over 2%, and Expedia Group jumping more than 4% [1][10][11] - American Airlines Group gained 3.5% after raising its revenue guidance for the current quarter, while United Airlines rose 3.2% [11] Oil Prices and Economic Impact - Concerns over prolonged supply disruptions due to the closure of the Strait of Hormuz have kept crude prices near $100 a barrel [2][11] - The Federal Reserve is expected to keep borrowing costs unchanged, with rate futures suggesting a potential 25-basis-point cut toward the end of the year, down from around two before the conflict [4][11] Market Performance - The S&P 500 climbed 0.25% to end at 6,716.09 points, with eight of the eleven sector indexes rising, led by energy, which was up 1.02% [7][11] - The S&P 500 financials sector index rebounded 0.5%, with asset managers Blackstone, Apollo Global, and KKR seeing gains of 4.6%, 5.3%, and 3.3% respectively [6][11] Trading Volume and Stock Movements - Trading volume on U.S. exchanges was light, with 16.9 billion shares traded compared to an average of 19.8 billion shares over the previous 20 sessions [8][11] - Energy companies Occidental and ConocoPhillips rose about 1% each, tracking higher crude prices [8][11] - Eli Lilly fell nearly 6% after being downgraded by HSBC from "hold" to "reduce" [9][11]

Core Viewpoint - The weight loss drug market is emerging as a significant growth opportunity in the pharmaceutical industry, comparable to the technology sector, with Eli Lilly and Viking Therapeutics as key players [1][2]. Eli Lilly - Eli Lilly leads the weight loss drug market with a 60% share, driven by its products Mounjaro and Zepbound, which have shown triple-digit revenue growth [5][13]. - The company entered the GLP-1 drug market after Novo Nordisk and has focused on increasing manufacturing capacity to meet demand [4][5]. - Lilly's oral weight loss drug is currently under regulatory review, potentially expanding its market presence [6]. Viking Therapeutics - Viking Therapeutics is advancing its candidate VK2735 into phase 3 trials, with promising results suggesting it could compete effectively with Lilly and Novo's offerings [8][9]. - The company has another candidate targeting amylin and calcitonin receptors, which are important for metabolism [10]. - Demand for weight loss drugs is high, providing Viking with an opportunity to capture market share if its trials are successful [10]. Investment Considerations - Both Eli Lilly and Viking Therapeutics are viewed as strong investment opportunities in the weight loss drug market, with Lilly currently generating significant revenue and Viking showing potential for future growth [13][15]. - Lilly's stock has seen a decline of about 8% this year, trading at 28 times forward earnings estimates, while Viking's stock has increased by approximately 2% this year [13][14]. - The upcoming regulatory decision on Lilly's oral weight loss drug could serve as a catalyst for its stock price [15].

It has been a wild ride for Hims & Hers (NYSE: HIMS) shareholders over the last few years. The stock is currently in a 65% drawdown from its highs, but up 50% in March, due to the telehealth platform's latest deal with a weight-loss drugmaker that was formerly suing it. Now, Hims & Hers is teaming up with its former enemies. Here are two S&P 500 index stocks to watch after this latest Hims & Hers stock move, and what it means for the future of the weight-loss market. Will AI create the world's first trill ...